US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US5110587A
(en)
|
1981-12-24 |
1992-05-05 |
Health Research, Incorporated |
Immunogenic composition comprising synthetically modified vaccinia virus
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
US5174993A
(en)
|
1981-12-24 |
1992-12-29 |
Health Research Inc. |
Recombinant avipox virus and immunological use thereof
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
US5833975A
(en)
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
ZA836080B
(en)
|
1982-08-23 |
1984-04-25 |
Scripps Clinic Res |
Broad spectrum influenza antisera
|
US4693981A
(en)
|
1983-12-20 |
1987-09-15 |
Advanced Genetics Research Institute |
Preparation of inactivated viral vaccines
|
US5106619A
(en)
|
1983-12-20 |
1992-04-21 |
Diamond Scientific Co. |
Preparation of inactivated viral vaccines
|
US5182192A
(en)
|
1987-03-27 |
1993-01-26 |
The Wistar Institute |
Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
US6001634A
(en)
|
1989-08-28 |
1999-12-14 |
Palese; Peter |
Recombinant negative strand RNA viruses
|
US5166057A
(en)
|
1989-08-28 |
1992-11-24 |
The Mount Sinai School Of Medicine Of The City University Of New York |
Recombinant negative strand rna virus expression-systems
|
US5854037A
(en)
|
1989-08-28 |
1998-12-29 |
The Mount Sinai School Of Medicine Of The City University Of New York |
Recombinant negative strand RNA virus expression systems and vaccines
|
US20060019350A1
(en)
|
1989-08-28 |
2006-01-26 |
Peter Palese |
Recombinant negative strand RNA virus expression system and vacccines
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
US6887699B1
(en)
|
1990-05-22 |
2005-05-03 |
Medimmune Vaccines, Inc. |
Recombinant negative strand RNA virus expression systems and vaccines
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
FR2664905B1
(fr)
|
1990-07-18 |
1994-08-12 |
Agronomique Inst Nat Rech |
Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US6034298A
(en)
|
1991-08-26 |
2000-03-07 |
Prodigene, Inc. |
Vaccines expressed in plants
|
US5484719A
(en)
|
1991-08-26 |
1996-01-16 |
Edible Vaccines, Inc. |
Vaccines produced and administered through edible plants
|
US5612487A
(en)
|
1991-08-26 |
1997-03-18 |
Edible Vaccines, Inc. |
Anti-viral vaccines expressed in plants
|
PT1696031E
(pt)
|
1991-12-02 |
2010-06-25 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
US6022726A
(en)
|
1992-02-03 |
2000-02-08 |
Palese; Peter |
Genetically engineered attenuated viruses
|
US5589174A
(en)
|
1992-09-17 |
1996-12-31 |
Takara Shuzo Co., Ltd. |
Anti-human influenza virus antibody
|
JP3037554B2
(ja)
|
1993-04-20 |
2000-04-24 |
寳酒造株式会社 |
免疫原性人工ポリペプチド
|
EP0621339B1
(en)
|
1992-09-17 |
2001-10-24 |
Takara Shuzo Co. Ltd. |
Immunogenic human influenza A virus haemagglutinin polypeptides
|
US6337070B1
(en)
|
1993-04-29 |
2002-01-08 |
Takara Shuzo Co., Ltd. |
Polypeptides for use in generating anti-human influenza virus antibodies
|
GB9221654D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant human anti-cytomegalovirus antibodies
|
US5674703A
(en)
|
1992-12-02 |
1997-10-07 |
Woo; Savio L. C. |
Episomal vector systems and related methods
|
WO1994016109A1
(en)
|
1993-01-15 |
1994-07-21 |
Whitehead Institute For Biomedical Research |
Membrane fusion events and means for altering same
|
WO1994017826A1
(en)
|
1993-02-01 |
1994-08-18 |
Smithkline Beecham Corporation |
Vaccinal polypeptides
|
US5573916A
(en)
|
1994-05-19 |
1996-11-12 |
Coretech, Inc. |
Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
|
US5505947A
(en)
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
PT702085E
(pt)
|
1994-07-18 |
2004-04-30 |
Karl Klaus Conzelmann |
Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
|
AU712714B2
(en)
|
1994-10-03 |
1999-11-11 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
|
KR100654645B1
(ko)
|
1995-04-27 |
2007-04-04 |
아브게닉스, 인크. |
면역화된 제노마우스 유래의 인간 항체
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
DE69510207T3
(de)
|
1995-08-09 |
2007-02-15 |
Schweiz. Serum- & Impfinstitut Bern |
Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
|
ES2326705T3
(es)
|
1995-09-14 |
2009-10-16 |
Virginia Tech Intellectual Properties, Inc. |
Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
|
US6264957B1
(en)
|
1995-09-27 |
2001-07-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Product of infectious respiratory syncytial virus from cloned nucleotide sequences
|
JP2820106B2
(ja)
|
1996-02-29 |
1998-11-05 |
日本電気株式会社 |
トラヒックシェーパ装置
|
CA2252439C
(en)
|
1996-04-19 |
2014-09-30 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
|
AU734532B2
(en)
|
1996-04-19 |
2001-06-14 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
|
KR100658491B1
(ko)
|
1996-07-15 |
2006-12-18 |
더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 |
클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산
|
US20050032211A1
(en)
|
1996-09-26 |
2005-02-10 |
Metabogal Ltd. |
Cell/tissue culturing device, system and method
|
IL155588A0
(en)
|
2003-04-27 |
2003-11-23 |
Metabogal Ltd |
Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
|
JP2000517194A
(ja)
|
1996-09-27 |
2000-12-26 |
アメリカン・サイアナミド・カンパニー |
モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
KR20080059467A
(ko)
|
1996-12-03 |
2008-06-27 |
아브게닉스, 인크. |
복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
|
US5891705A
(en)
|
1997-04-08 |
1999-04-06 |
Pentose Pharmaceuticals, Inc. |
Method for inactivating a virus
|
KR100663319B1
(ko)
|
1997-04-14 |
2007-01-02 |
마이크로메트 에이지 |
인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
CN1250725C
(zh)
|
1997-05-23 |
2006-04-12 |
美国政府健康及人类服务部 |
从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
PT1012244E
(pt)
|
1997-07-11 |
2007-08-21 |
Univ Yale |
''rabdovírus com revestimentos remanipulados''
|
BR9812232A
(pt)
|
1997-09-19 |
2000-07-18 |
American Cyanamid Co |
Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
|
ATE384126T1
(de)
|
1998-06-12 |
2008-02-15 |
Sinai School Medicine |
Interferon induzierende genetisch veränderte attenuierte viren
|
DK1086207T3
(da)
|
1998-06-12 |
2007-05-29 |
Sinai School Medicine |
Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
|
US6544785B1
(en)
|
1998-09-14 |
2003-04-08 |
Mount Sinai School Of Medicine Of New York University |
Helper-free rescue of recombinant negative strand RNA viruses
|
US6146642A
(en)
|
1998-09-14 |
2000-11-14 |
Mount Sinai School Of Medicine, Of The City University Of New York |
Recombinant new castle disease virus RNA expression systems and vaccines
|
AU776855B2
(en)
|
1998-12-23 |
2004-09-23 |
Boyce Thompson Institute For Plant Research Inc. |
Expression of immunogenic hepatitis B surface antigens in transgenic plants
|
AT407958B
(de)
|
1999-02-11 |
2001-07-25 |
Immuno Ag |
Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
|
US8715940B2
(en)
|
1999-04-06 |
2014-05-06 |
Wisconsin Alumni Research Foundation |
Method of making recombinant influenza virus
|
MXPA01010921A
(es)
|
1999-04-29 |
2003-06-24 |
Syngenta Ltd |
Plantas resistentes a herbicidas.
|
DE122007000061I2
(de)
|
1999-07-14 |
2011-07-21 |
Sinai School Medicine |
In vitro-rekonstitution von segmentierten negativstrang-rna-viren.
|
AU764368B2
(en)
|
1999-09-24 |
2003-08-14 |
Smithkline Beecham Biologicals (Sa) |
Intranasal influenza virus vaccine
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US6770799B2
(en)
|
2000-03-17 |
2004-08-03 |
Thompson Boyce Plant Res |
Expression of recombinant human acetylcholinesterase in transgenic plants
|
WO2001083794A2
(en)
|
2000-04-28 |
2001-11-08 |
St. Jude Children's Research Hospital |
Dna transfection system for the generation of infectious influenza virus
|
US6632620B1
(en)
|
2000-06-22 |
2003-10-14 |
Andrew N. Makarovskiy |
Compositions for identification and isolation of stem cells
|
ATE376059T1
(de)
|
2000-06-23 |
2007-11-15 |
Wyeth Corp |
Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
|
US7132510B2
(en)
|
2000-12-29 |
2006-11-07 |
Bio-Technology General (Israel) Ltd. |
Specific human antibodies for selective cancer therapy
|
HUE050222T2
(hu)
|
2002-02-13 |
2020-11-30 |
Wisconsin Alumni Res Found |
Szignál influenzavírus-vektorok pakolására
|
US20040091503A1
(en)
|
2002-08-20 |
2004-05-13 |
Genitrix, Llc |
Lectin compositions and methods for modulating an immune response to an antigen
|
EP1594888A4
(en)
|
2003-01-29 |
2007-08-29 |
Univ New York State Res Found |
TOLERANCE-INDUCED TARGET PRODUCTION OF ANTIBODIES
|
EP1594536B1
(en)
|
2003-01-30 |
2009-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Adjuvanted influenza vaccine
|
US7695725B2
(en)
|
2003-02-06 |
2010-04-13 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
JP4368594B2
(ja)
|
2003-02-24 |
2009-11-18 |
株式会社インシリコサイエンス |
タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
|
US7951557B2
(en)
|
2003-04-27 |
2011-05-31 |
Protalix Ltd. |
Human lysosomal proteins from plant cell culture
|
BRPI0410340A
(pt)
|
2003-05-05 |
2006-05-30 |
Dow Agrosciences Llc |
vetores e células para preparar composições imunoprotetoras derivadas de plantas transgênicas
|
CA2897608C
(en)
|
2003-05-09 |
2018-07-31 |
Duke University |
Cd20-specific antibodies and methods employing same
|
EP1633312A4
(en)
*
|
2003-06-16 |
2012-09-26 |
Medimmune Llc |
INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
|
US8592197B2
(en)
|
2003-07-11 |
2013-11-26 |
Novavax, Inc. |
Functional influenza virus-like particles (VLPs)
|
US8551756B2
(en)
*
|
2003-07-11 |
2013-10-08 |
Novavax, Inc. |
Avian influenza chimeric VLPS
|
PT2261378E
(pt)
|
2003-11-04 |
2013-12-09 |
Univ Tulane |
Método de prevenção da fusão vírus:células através da inibição da função da região de iniciação de fusão em vírus de rna contendo proteínas do invólucro fusogénico de membrana de classe i
|
CA2568020C
(en)
|
2004-05-25 |
2015-04-07 |
Medimmune Vaccines, Inc. |
Influenza hemagglutinin and neuraminidase variants
|
MX2007004414A
(es)
|
2004-10-13 |
2007-09-25 |
Protalix Ltd |
Sistema y metodo para la produccion de anticuerpos en cultivos de celulas de plantas.
|
EP1814990A2
(en)
|
2004-11-19 |
2007-08-08 |
Wisconsin Alumni Research Foundation |
Recombinant influenza vectors with tandem transcription units
|
US8137676B2
(en)
|
2005-02-15 |
2012-03-20 |
Mount Sinai School Of Medicine |
Genetically engineered equine influenza virus and uses thereof
|
US7566454B2
(en)
|
2005-02-24 |
2009-07-28 |
University Of Massachusetts |
Influenza nucleic acids, polypeptides, and uses thereof
|
AU2006227571B8
(en)
|
2005-03-24 |
2011-01-27 |
Life Sciences Research Partners Vzw |
Novel anti-PlGF antibody
|
AU2006252406B2
(en)
|
2005-06-01 |
2012-05-17 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
JP4758148B2
(ja)
|
2005-06-14 |
2011-08-24 |
泰三 宇田 |
インフルエンザウイルスのヘマグルチニンに対する抗体酵素
|
US7951384B2
(en)
|
2005-08-05 |
2011-05-31 |
University Of Massachusetts |
Virus-like particles as vaccines for paramyxovirus
|
CN102727885A
(zh)
|
2005-11-04 |
2012-10-17 |
诺华疫苗和诊断有限公司 |
包含颗粒佐剂和免疫增强剂组合的流感疫苗
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
US9387242B2
(en)
|
2005-12-02 |
2016-07-12 |
Icahn School Of Medicine At Mount Sinai |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
CA2632483C
(en)
|
2005-12-06 |
2014-11-25 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Improved influenza vaccine
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
BRPI0707733B1
(pt)
|
2006-02-13 |
2019-12-31 |
Fraunhofer Usa Inc |
antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
|
US20070207171A1
(en)
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
CA2638760A1
(en)
|
2006-03-07 |
2007-09-13 |
Vaxinnate Corporation |
Compositions that include hemagglutinin, methods of making and methods of use thereof
|
CA2646891A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
JP2009534303A
(ja)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
JP2009532352A
(ja)
|
2006-03-31 |
2009-09-10 |
ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション |
ワクチンのための高力価組み換えインフルエンザ・ウィルス
|
US9101578B2
(en)
|
2006-05-01 |
2015-08-11 |
Technovax, Inc. |
Polyvalent influenza virus-like particle (VLP) compositions
|
US20070262178A1
(en)
|
2006-05-12 |
2007-11-15 |
Ultradent Products, Inc. |
Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
|
US20080014205A1
(en)
|
2006-05-15 |
2008-01-17 |
Lawrence Horowitz |
Neutralizing Antibodies to Influenza Viruses
|
US8148085B2
(en)
|
2006-05-15 |
2012-04-03 |
Sea Lane Biotechnologies, Llc |
Donor specific antibody libraries
|
DK2023952T3
(en)
|
2006-05-18 |
2015-10-19 |
Epimmune Inc |
Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
|
US20100143406A1
(en)
|
2006-06-30 |
2010-06-10 |
Gale Smith |
Methods of enhancing protein incorporation into virus like particles
|
WO2008011636A2
(en)
|
2006-07-21 |
2008-01-24 |
California Institute Of Technology |
Targeted gene delivery for dendritic cell vaccination
|
MY170607A
(en)
|
2006-09-07 |
2019-08-20 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
EP2716656B1
(en)
|
2007-06-15 |
2016-10-12 |
Xiamen University |
Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof
|
EP2014279A1
(en)
|
2007-06-22 |
2009-01-14 |
Pevion Biotech AG |
Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
|
CA2692200A1
(en)
|
2007-06-27 |
2008-12-31 |
Novartis Ag |
Low-additive influenza vaccines
|
CA2615372A1
(en)
|
2007-07-13 |
2009-01-13 |
Marc-Andre D'aoust |
Influenza virus-like particles (vlps) comprising hemagglutinin
|
JP5187883B2
(ja)
|
2007-07-18 |
2013-04-24 |
独立行政法人科学技術振興機構 |
抗原ペプチドおよびその利用
|
EP2175883A4
(en)
|
2007-07-19 |
2011-11-30 |
Novavax Inc |
CHIMERIC VARICELLA ZOSTER VIRUS-VIRUSUAL PARTICLES
|
US20090092635A1
(en)
|
2007-08-17 |
2009-04-09 |
Wyeth |
Heterologous prime-boost immunization regimen
|
EP2200639B1
(en)
|
2007-09-24 |
2016-03-30 |
Government of the USA, as Represented by the Secretary, Department of Health and Human Services |
Immunostimulatory combinations of tlr3 ligands with tlr2 and tlr9 agonists and methods of use
|
FR2921387B1
(fr)
|
2007-09-26 |
2012-04-20 |
Sanofi Pasteur |
Procede de production du virus de la grippe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
CA2707235C
(en)
|
2007-11-27 |
2013-11-19 |
Medicago Inc. |
Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
|
EP2222701B1
(en)
|
2007-12-06 |
2017-11-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
WO2009092038A1
(en)
|
2008-01-16 |
2009-07-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Influenza dna vaccination and methods of use thereof
|
ITTO20080204A1
(it)
|
2008-03-17 |
2009-09-18 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
|
AU2009228058A1
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to viral antigens
|
GB0905570D0
(en)
|
2009-03-31 |
2009-05-13 |
Novartis Ag |
Combined vaccines
|
EP2310409A2
(en)
|
2008-06-17 |
2011-04-20 |
Apogenix GmbH |
Multimeric tnf receptors
|
JP5756750B2
(ja)
|
2008-06-25 |
2015-07-29 |
インセルム(インスティチュート ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) |
フラジェリンに基づく新規の免疫アジュバント化合物及びその使用
|
DK2294202T3
(en)
|
2008-07-08 |
2015-08-31 |
Medicago Inc |
SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
|
WO2010036170A1
(en)
|
2008-09-23 |
2010-04-01 |
Nexam Chemical Ab |
Acetylenic polyamide
|
WO2010036948A2
(en)
|
2008-09-26 |
2010-04-01 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Dna prime/inactivated vaccine boost immunization to influenza virus
|
WO2010111687A2
(en)
|
2009-03-27 |
2010-09-30 |
Academia Sinica |
Methods and compositions for immunization against virus
|
WO2010117786A1
(en)
|
2009-03-30 |
2010-10-14 |
Mount Sinai School Of Medicine Of New York University |
Influenza virus vaccines and uses thereof
|
MY183517A
(en)
|
2009-05-11 |
2021-02-24 |
Janssen Vaccines & Prevention Bv |
Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
|
WO2010138564A1
(en)
|
2009-05-26 |
2010-12-02 |
Mount Sinai School Of Medicine Of New York University |
Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
|
BRPI1015053A2
(pt)
|
2009-06-24 |
2019-07-09 |
Medicago Inc |
partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
|
JP5845180B2
(ja)
|
2009-07-30 |
2016-01-20 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルス及びそれらの使用
|
JP5463107B2
(ja)
|
2009-09-14 |
2014-04-09 |
独立行政法人国立国際医療研究センター |
新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
|
US20120219584A1
(en)
|
2009-10-05 |
2012-08-30 |
The United States Of America As Represented By The Secretary, Department Of Health |
Protection against pandemic and seasonal strains of influenza
|
JP2013060367A
(ja)
|
2010-01-15 |
2013-04-04 |
Osaka Univ |
抗インフルエンザ抗体及びインフルエンザ検出用デバイス
|
WO2011091376A2
(en)
|
2010-01-24 |
2011-07-28 |
Biological Mimetics, Inc. |
Immunogenic influenza composition
|
US8298820B2
(en)
|
2010-01-26 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Influenza nucleic acid molecules and vaccines made therefrom
|
BR112012020839A2
(pt)
|
2010-02-18 |
2017-11-21 |
Sinai School Medicine |
vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
JP5795340B2
(ja)
|
2010-03-08 |
2015-10-14 |
セルトリオン インクCelltrion,Inc. |
インフルエンザa型ウイルスに対して中和活性を有するヒトb細胞由来のヒトモノクローナル抗体
|
JP2013526849A
(ja)
|
2010-03-30 |
2013-06-27 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルスワクチン及びその使用
|
HUE030724T2
(en)
|
2010-04-09 |
2017-06-28 |
Univ Utrecht Holding Bv |
Recombinant multimer influenza proteins
|
NZ603226A
(en)
|
2010-04-30 |
2015-02-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
WO2012009790A1
(en)
|
2010-07-22 |
2012-01-26 |
Schrader John W |
Cross-protective pathogen protection, methods and compositions thereof
|
US9512182B2
(en)
|
2010-12-13 |
2016-12-06 |
University Of Utah Research Foundation |
Vaccine antigens that direct immunity to conserved epitopes
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
SG11201400743VA
(en)
*
|
2011-09-20 |
2014-04-28 |
Sinai School Medicine |
Influenza virus vaccines and uses thereof
|
EP3566714A1
(en)
|
2011-11-28 |
2019-11-13 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
WO2013174403A1
(en)
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
CN103665155B
(zh)
|
2012-09-14 |
2016-07-06 |
中国科学院上海生命科学研究院 |
一种抗流感病毒广谱中和性的中和分子1f2
|
KR101452865B1
(ko)
|
2012-09-17 |
2014-10-21 |
서울대학교산학협력단 |
신규한 ip-10 에피토프 및 이에 대한 항체
|
CA2894506C
(en)
|
2012-12-11 |
2021-08-10 |
Vib Vzw |
Anti-influenza antibody
|
AU2013362935B2
(en)
|
2012-12-18 |
2018-10-04 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccines and uses thereof
|
WO2014108515A1
(en)
|
2013-01-10 |
2014-07-17 |
Novartis Ag |
Influenza virus immunogenic compositions and uses thereof
|
JP6462591B2
(ja)
|
2013-02-22 |
2019-01-30 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規抗体コンジュゲートおよびその使用
|
CN111334530A
(zh)
|
2013-03-13 |
2020-06-26 |
诺华股份有限公司 |
乙型流感病毒重配
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
US20140286981A1
(en)
|
2013-03-14 |
2014-09-25 |
Wisconsin Alumni Research Foundation |
Broadly reactive mosaic peptide for influenza vaccine
|
WO2014152841A1
(en)
|
2013-03-14 |
2014-09-25 |
Contrafect Corporation |
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
JP2016517414A
(ja)
|
2013-03-15 |
2016-06-16 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
インフルエンザ核酸分子及びそれから作製したワクチン
|
WO2014151747A1
(en)
|
2013-03-15 |
2014-09-25 |
Ramot At Tel Aviv University Ltd. |
Methods and compositions with immune therapy for treatment of dementia
|
WO2015095002A1
(en)
|
2013-12-16 |
2015-06-25 |
Texas Tech University System |
Anti-ron monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy
|
PL235555B1
(pl)
|
2014-06-24 |
2020-09-07 |
Inst Biotechnologii I Antybiotykow |
Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
|
EA035375B1
(ru)
|
2014-07-10 |
2020-06-03 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцины против вируса гриппа и их применения
|
PE20170290A1
(es)
|
2014-07-10 |
2017-03-26 |
Janssen Vaccines And Prevention B V |
Vacunas contra virus de influenza y usos de las mismas
|
CN112979828A
(zh)
|
2014-07-17 |
2021-06-18 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
AU2016209032A1
(en)
|
2015-01-23 |
2017-08-10 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
EP3302559B1
(en)
|
2015-06-04 |
2022-01-12 |
University of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
WO2016205347A1
(en)
|
2015-06-16 |
2016-12-22 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccines and uses thereof
|
EP3322449A1
(en)
|
2015-07-16 |
2018-05-23 |
Cellerant Therapeutics, Inc. |
Cysteine-substituted immunoglobulins
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
CN114848240A
(zh)
|
2015-08-27 |
2022-08-05 |
捷迈有限公司 |
方向锁定反转式肩部假体和系统
|
US20200237898A1
(en)
|
2015-09-21 |
2020-07-30 |
Oregon Health & Science University |
Vaccines intelligently produced by epitope recombination (viper) for influenza
|
US10063211B2
(en)
|
2016-02-03 |
2018-08-28 |
Qualcomm Incorporated |
Compact bypass and decoupling structure for millimeter-wave circuits
|
US10703803B2
(en)
|
2016-03-01 |
2020-07-07 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza B neuraminidase
|
US20190125859A1
(en)
|
2016-06-03 |
2019-05-02 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
EP3255056A1
(en)
|
2016-06-06 |
2017-12-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
|
JP7237344B2
(ja)
|
2016-06-15 |
2023-03-13 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルス血球凝集素タンパク質及びその使用
|
SG10201912556VA
(en)
|
2016-07-20 |
2020-02-27 |
Aerpio Therapeutics Inc |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
JP7132230B2
(ja)
|
2017-02-10 |
2022-09-06 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
Trailショート抗体及び使用方法
|
WO2018187706A2
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
WO2019032463A1
(en)
|
2017-08-07 |
2019-02-14 |
Icahn School Of Medicine At Mount Sinai |
IMMUNOGENIC COMPOSITIONS COMPRISING INFLUENZA VIRUS AND AS01 CHIMERIC POLYPEPTIDES OF HEMAGGLUTININ AND USES THEREOF
|
CA3104297A1
(en)
|
2018-06-21 |
2019-12-26 |
Icahn School Of Medicine At Mount Sinai |
Mosaic influenza virus hemagglutinin polypeptides and uses thereof
|
WO2020219719A1
(en)
|
2019-04-24 |
2020-10-29 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
WO2020264141A1
(en)
|
2019-06-26 |
2020-12-30 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus neuraminidase and uses thereof
|
CN115003328A
(zh)
|
2019-10-22 |
2022-09-02 |
西奈山伊坎医学院 |
重组神经氨酸酶及其用途
|